Download A4Medicine Mobile App
Empower Your RCGP AKT Journey: Master the MCQs with Us! 🚀
The following table provides a concise overview of the key cautions and side effects associated with Denosumab, a human monoclonal antibody used in the treatment of various bone-related conditions. This information is sourced from the British National Formulary (BNF) and the Medicines and Healthcare Products Regulatory Agency (MHRA), ensuring that it is based on authoritative and up-to-date guidelines. Denosumab acts by inhibiting osteoclast formation, function, and survival, ultimately reducing bone resorption.
This table serves as a valuable reference, providing a quick and organized summary of the critical considerations when prescribing or administering Denosumab.
| Aspect | Cautions/Warnings/SEs |
|---|---|
| Atypical Femoral Fractures | Rare in long-term use (>2.5 years) for postmenopausal osteoporosis. Patients should report thigh, hip, or groin pain during treatment. Consider discontinuation if suspected fracture. |
| Osteonecrosis of the Jaw (ONJ) | Common in cancer patients. Risk factors include smoking, old age, poor oral hygiene, dental procedures, comorbidity, advanced cancer, previous bisphosphonate use, and concomitant treatments. Dental exam before treatment. Avoid in patients with dental/jaw conditions requiring surgery. |
| Hypocalcaemia | Risk increases with renal impairment. Monitor plasma-calcium concentration. More frequent monitoring in severe renal impairment or if symptoms occur. |
| Osteonecrosis of External Auditory Canal | Consider in patients with ear symptoms during treatment, including chronic ear infections.... |
Try our Free Plan to get the full article.
